This Scottish Biotech Just Raised $46M to Tackle a Silent Kidney Threat

Jan de Vries · 2026-08-07

When a company lands a massive funding round, it's easy to skim past the headline. But the story behind Mironid's recent $46 million raise is about more than just money—it's about a potential breakthrough for millions of people living with a devastating genetic condition. The Glasgow-based biopharmaceutical firm just closed a Series B round that will push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. And if the science holds up, it could change how we treat this rare but all-too-common kidney disorder. ### The Big Picture on ADPKD ADPKD is the most common hereditary kidney disease out there. It affects over 12 million people globally, and here's the sobering stat: about 50% of patients will develop kidney failure by age 60. That's not a distant possibility—that's a ticking clock for half the people diagnosed. The disease is caused by mutations in the PKD1 or PKD2 genes. Those mutations lead to uncontrolled growth of fluid-filled cysts in the kidneys. Over time, those cysts crowd out healthy tissue, and the kidneys eventually fail. It's a slow, relentless progression that current treatments can only slow, not stop. ### Who's Backing This Bet? The Series B round was led by the Scottish National Investment Bank, but they're not alone. The syndicate includes heavy hitters like Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. That's a serious vote of confidence from both strategic pharma investors and seasoned VCs. Neil Wilkie, Mironid's CEO, didn't mince words about what this means. "Securing funding from such a high-calibre syndicate is a strong validator of our approach to treating kidney diseases such as ADPKD," he said. The money will let the company advance clinical development of its lead candidate, bringing them closer to what Wilkie calls "transforming the treatment landscape." ### The Science: Targeting cAMP Directly So what's actually different about Mironid's approach? It comes down to a molecule called cyclic AMP (cAMP), a cellular signal that's active at every stage of ADPKD—from the very start all the way to end-stage disease. cAMP drives both cell proliferation and fluid secretion inside the cysts. That's the engine of the disease. Mironid's LoAc molecules are designed to hit cAMP directly. Preclinical data shows significant efficacy across disease endpoints, including reductions in cyst number and kidney volume. The company argues that by preventing new cyst formation and arresting growth of existing ones, this approach could be more durable and have a better side-effect profile than current therapies. That's a bold claim, but the early data seems to back it up. ### A Pipeline Beyond ADPKD ADPKD is the lead program, but it's not the whole story. Mironid's pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways tied to disease progression. The company is focused on degenerative and rare genetic kidney diseases, plus major inflammatory conditions and cancer. So this isn't a one-trick pony—it's a platform. ### The Scottish Biotech Momentum Mironid spun out of the University of Strathclyde and Heriot-Watt University back in 2015. That's a long runway, built on more than three decades of research into PDE biology by Professor Miles Houslay. The company is headquartered in Glasgow, and Paul Callaghan, Investment Director at the Scottish National Investment Bank, sees this as proof of Scotland's growing biotech reputation. "Mironid exemplifies Scotland's growing reputation for biotech innovation," Callaghan said, adding that the goal is to "translate world-class research into clinical progress, commercial opportunity and potential patient benefit." ### What This Funding Actually Buys This Series B follows an earlier Series A extension round. Combined, Mironid has now raised about $46.7 million in total funding since inception. The proceeds will go toward advancing the LoAc candidate through clinical trials—the expensive, critical phase where promising science either becomes a real therapy or falls apart. For patients with ADPKD, the stakes couldn't be higher. Current treatments can slow cyst growth, but they don't stop it. A therapy that directly targets the underlying cAMP signaling could offer something genuinely new: a way to halt the disease's progression rather than just manage its symptoms. It's still early days, and clinical trials are where many promising drugs go to die. But with this kind of investor backing and a novel mechanism of action, Mironid is worth watching. If the data continues to look good, this Scottish biotech could be on the path to something truly meaningful.